Brexit and the Regulation of Health Products – Latest Information
The UK is due to leave the European Union. How and when they leave is not yet certain. Any kind of Brexit will mean some things are going to change. Whether you're a concerned citizen or wondering how Brexit may affect your business, visit the Government website gov.ie/brexit to keep up to date on the latest news and advice.
The HPRA will provide information on this dedicated section of our website to keep stakeholders informed of developments related to Brexit and the health products we regulate.
Please see our detailed Brexit guidance document for human and veterinary medicines (last updated 18 October 2018). You can also visit the dedicated Medical Devices Brexit page or Cosmetics page for relevant updates. Our additional background information relating to Brexit is also available.
The HPRA continues to advise companies to engage with us at the earliest opportunity if they believe that Brexit may impact on their ability to supply a health product to the Irish market.
Companies can submit Brexit queries to the relevant e-mail address below:
Human Medicines – email@example.com
Veterinary Medicines – firstname.lastname@example.org
Medical Devices – email@example.com Cosmetics - firstname.lastname@example.org
17 April 2019 Have you verified if your cosmetic product has a Responsible Person registered within the EU-27 member states?
On 1 February 2019, the EU Commission published a Q&A document to provide further information on the impact of a no deal Brexit on cosmetic products (and other products covered under the New Approach legislation).
This Q&A follows on from the Commissions’ January 2018 notice to stakeholders and November 2018 notice to stakeholders, and highlights some of the implications on labelling, representation and supply in the event of no deal.
The latest Q&A provides examples of when goods are placed on the market and in the supply chain, which includes clarification on the requirements in relation to presentation of the Responsible Person (RP) contact details on the labelling.
The Q&A also reinforces the importance of updating the Cosmetic Product Notification Portal (CPNP) for products currently registered with a RP in the UK. In the event of a no-deal Brexit, all cosmetic products made available to the EU market as of the date of withdrawal date are required to be registered on CPNP with a RP of one of the EU-27 member states. Information is available regarding transfer of an existing notification in CPNP to a future EU-RP in the Commission’s November 2018 notice to stakeholders.
In the context of the UK becoming a 3rd country post Brexit, the HPRA takes this opportunity to remind Irish entities sourcing products from the UK for supply to the EU-27 to be aware that they will become an importer and potentially the RP for the product if one has not already been designated in the EU-27.
The HPRA is continuing to work with the European Commission and other Member States in relation to cosmetic product issues arising from Brexit.
The HPRA encourages any responsible persons, distributors, manufacturers or retailers to take the appropriate steps in preparation for Brexit in relation to supply of compliant cosmetic products to the market. If there are any specific queries, these can be sent to email@example.com.
EU Commission Q&A
EU Commission Notice to Stakeholders January 2018 EU Commission Notice to Stakeholders November 2018
26 March 2019 - European Medicines Agency publishes Brexit questions-and-answers document
The EMA has published a Q&A document for patients, healthcare professionals and the general public on the preparatory work that European Union authorities are doing to prevent medicine shortages due to the United Kingdom’s withdrawal from the EU.
It explains that in case of a withdrawal agreement, there will be a transition period during which EU law will continue to apply in the United Kingdom. This means that access to medicines will not be affected.
If the UK leaves without a withdrawal agreement or deal (‘no-deal scenario’), EU law will cease to apply in the UK. In this case, in order to be able to continue to supply medicines in the EU, companies carrying out certain activities in the UK will need to make changes to comply with EU law.
27 February 2019 - Government publishes a further range of practical advice to help businesses and citizens get Brexit ready
While there is still a lot of uncertainty about how and when the UK will leave the European Union, it’s important for you to be aware of what Brexit may mean for your business and your daily life. The Government has today published a further range of practical advice on the gov.ie/brexit website. This content will be updated regularly as more information becomes available.
26 February 2019 - European Commission statement on the withdrawal of the UK and EU rules for batch testing of medicinal products
The European Commission has published (25 February 2019) a communication entitled Withdrawal of the UK and EU rules for batch testing of medicinal products.
In relation to quality control (QC) testing, the Commission has noted that there may be objective reasons beyond the control of marketing authorisation holders (MAHs) that may prevent timely transfer of QC testing to an EU/EEA site by the withdrawal date. The Commission letter outlines circumstances under which competent authorities may allow, by way of exemption, on-going release of medicines onto the EU market based on QC testing performed in the UK. Please note that these provisions are subject to conditions and will apply for a limited time period up until end December 2019 at the latest.
The Commission also outlines in this statement that a batch release site in the EU 27 will need to be identified by the MAH before 29 March 2019 so that on-going EU compliance can be assured post withdrawal.
Applications for an exemption must be submitted as soon as possible and in no case later than 29 March 2019. The HPRA is inviting companies who may wish to submit such an application to contact us as soon as possible for details of the procedure involved.
Companies are reminded that the MAH must be EU based as of 30 March 2019 and any outstanding MAH transfers must be urgently submitted to allow processing by the withdrawal date.
The HPRA remains available to discuss particular challenges presenting to stakeholders and in particular would welcome the opportunity to clarify any aspects of this exemption process with your Brexit representatives in the coming days. Please using the relevant e-mail address above.
18 February 2019 - Businesses urged to contact suppliers to ensure continuity of supply of goods and services post Brexit
According to the Minister for Business, Enterprise and Innovation, Heather Humphreys TD, “whether a business is a construction company, local beauty salon, bakery or even an Irish base of a multinational medical device company, it is crucial that they check their supply chains for vulnerabilities to Brexit impacts".
The Department of Business, Enterprise and Innovation (DBEI) website lists an extensive range of available supports and resources that are focused on Getting Business Brexit Ready. This includes advice from the European Commission on the seven things businesses need to know to prepare for Brexit. Businesses within the EU27 are encouraged to use this list to understand the impacts that Brexit is likely to have on their business, and to guide their preparations.
7 February 2019 - Preparing for Brexit: Advice for Irish-owned life sciences businesses
Enterprise Ireland has published a helpful article for Irish-owned life sciences businesses on the potential impact of Brexit. It is based on the advice and guidance provided by the HPRA to approximately 400 industry representatives who attended our recent Brexit stakeholder event.
The Enterprise Ireland Prepare for Brexit website has a wide range of supports, including online customs training and a range of helpful insights, to enable Irish businesses to take critical action and address their exposure to Brexit.
1 February 2019 - EU Commission publish updated Brexit Q&A on medical devices
On 1 February 2019, the EU Commission published a Q&A document to provide further information on the impact of a no deal Brexit on medical devices (and other products covered under the New Approach legislation).
This Q&A follows on form the Commission's 2018 notice to stakeholders and highlights some of the implications on certification, labelling, representation and supply in the event of no deal.
The latest Q&A provides examples of when goods are placed on the market and in the supply chain which clarifies the validity of certification from a Notified Body for example. It also provides some clarification from the EU Commission’s perspective on the transfer of Notified Body certificates.
The HPRA is continuing to work with the European Commission and other Member States in relation to medical devices issues arising from Brexit.
The HPRA encourages any patients, healthcare providers, notified bodies, distributors, manufacturers or their authorised representatives who have a specific question or concern about medical devices supply or other devices issues, in the context of a "no-deal" Brexit, to contact us on firstname.lastname@example.org or the medical device department directly on +353 1 634 3453.
EU Commission Q&A
EU Commission Notice to Stakeholders January 2018
1 February 2019 - EU Commission and EMA publish updated Brexit Q&A for human and veterinary medicines
The EU Commission and EMA have today published an updated list of questions and answers related to the United Kingdom's withdrawal from the EU. The focus of this Q&A is on the regulation of medicinal products for human and veterinary use within the framework of the Centralised Procedure.
Significantly, the latest Q&A confirms that dual UK and Irish labels are acceptable where the labels meet the requirements of the Directive and reflect the SPC in Ireland. See Question 24 for further details.
The websites of the Commission and of the European Medicines Agency provide additional information. For products authorised in decentralised or mutual recognition procedures, additional information is available through the websites of the Coordination Groups – the CMDh and the CMDv. These pages will be updated with further information, where necessary.
30 January 2019 - Oireachtas Joint Committee on Health
Representatives from the Department of Health, the HSE and the HPRA appeared before the Joint Committee on Health on Wednesday, 30 January to discuss ‘Preparedness of the Health Sector for Brexit’. A key area of focus for the Committee was on the continuity of supply of medicines in the event of a 'no-deal' Brexit. The Secretary General of the Department of Health, Jim Breslin, outlined the significant work that has already taken place and the ongoing initiatives to minimise and address any risks to continuity of supply.
The Secretary General's Opening Statement to the Committee can be found on the Department's website. You can also view the full meeting on the Houses of the Oireachtas website.
25 January 2019 – Planning for a “No-Deal” Brexit
The HPRA is actively planning for a “no-deal” Brexit. Our goal is to support companies be ready for such an outcome on 29 March 2019.
Our key objective is to ensure protection of public and animal health by facilitating continued access to medicines in the event no deal is reached.
In respect of regulatory matters:
- We continue to encourage any company, MAH or manufacturer who identifies that they may have a regulatory issue to engage with so that we can seek to provide pragmatic regulatory solutions;
- We have already made it clear that we will continue to accept joint labels with the UK where those labels are appropriate for the Irish market.
- We are preparing a matrix of the regulatory requirements and considering how these might be addressed in a “no deal” scenario.
- We are reviewing supply chain and stock levels in Ireland, engaging with customs and reviewing specialist products that may be exposed to Brexit.
- We will utilise our existing shortages framework to work with all relevant stakeholders to manage any unavoidable short term delays arising from Brexit.
We continue to call on companies:
- To engage with the HPRA at the first opportunity if they believe that Brexit may impact on their ability to supply a human or veterinary medicines to the Irish market.
- Not to take a unilateral decision to cease supply to the Irish market based on regulatory issues without talking firstly to us at the HPRA.
- To review their supply chains to ensure they are robust, that the logistic companies can manage new custom requirements and that consideration of the requirements of the transiting protocol are considered and understood for those products transiting the UK.
25 January 2019 – "Getting Ireland Brexit Ready" website
On this site, you can find information about the Government’s most recent engagements, outreach events, and ongoing consultation work on Brexit. You can also find details of the resources and financial supports available from all Government Departments and Agencies to help businesses to prepare for Brexit. In addition, there is a comprehensive Frequently Asked Questions sections and access to key documents published by the Government outlining Ireland's negotiation strategy and preparations for the potential impacts of Brexit.
You can also subscribe to receive the Government Brexit Update newsletter. This newsletter service will allow you to receive the most reliable and up-to-date information, and gain greater insight into the steps the Government is taking to prepare for Brexit.
17 January 2019 – Preparations regarding the Supply of Medicines and Brexit
The Department of Health has published a short video which outlines the comprehensive and coordinated set of preparations to ensure the continuity of health services and supply of medical products in the event of a no-deal Brexit. This work involves the Department of Health, the HSE, the Health Products Regulatory Authority (HPRA) and other agencies engaging in intensive Brexit preparedness and contingency planning.
Further information is also available on the Department’s dedicated Brexit webpage.
14 January 2019 – Brexit Stakeholder Event on Friday, 1 February
The HPRA wishes to engage with industry stakeholders to outline the activities which the organisation is undertaking, to hear from them in respect of their ongoing preparatory actions and to discuss any regulatory matters and topics of mutual concern.
The meeting, which takes place on Friday 1 February, will focus on medicines for human and veterinary use as well as medical devices and will include short presentations from speakers, followed by an open forum to allow questions, identify areas of concerns and share information.
Further event Information including registration details